ArticlePharmaceutical research2026
Discovering the Differences of the Individual Batches of API and its Polymorphs Using Hansen Solubility Parameters.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposePhysicochemical stability of drug products depends on excipient-API (active pharmaceutical ingredient) compatibility, where interfacial interactions at the particle surface can initiate degradation pathways and solid-state transformations. Conventional compatibility approaches often emphasise bulk properties and may under-represent surface effects.
methodsA methodology based on Hansen solubility parameters (HSPs) determined by inverse gas chromatography (IGC) was applied to characterise API surface properties. Three model compounds (ramipril, sertraline hydrochloride, agomelatine) were analysed to compare polymorphic forms and production batches. Measurements were performed at infinite dilution using multiple molecular probes at several temperatures.
resultsThe HSP profiles showed pronounced differences between polymorphs and, importantly, between batches sharing the same polymorphic form. The data indicate that molecular packing, stereochemistry and processing history can measurably alter surface energetics, with direct implications for excipient compatibility and formulation robustness.
conclusionIGC-derived HSP analysis provides complementary, surface-sensitive information that can support excipient selection during early formulation development and help manage risks related to polymorphic variability and supplier-to-supplier differences. Further work should link HSP profiles to formulation performance metrics such as processability, compatibility and stability.
Indexed as
Identifiers
42481855What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.